Transforming the Treatment of Neuromuscular Diseases
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
Creating the new generation of genetic therapies
Advancing revolutionary therapies to treat degenerative neuromuscular diseases
Careers at PepGen
Seeking passionate individuals who can help us to create therapies to improve the future of people living with neuromuscular diseases
Latest Updates
PepGen Appoints Laurie Keating as Chair of Board of Directors
Keating brings strong experience as a life science executive and Board member BOSTON, January 19, …
PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations
PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice …
PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular …